Histogen announced a licensing agreement with Pineworld Capital to develop and commercialize its proprietary hair stimulating complex in China, according to a press release.
Results from two company-sponsored and one investigator-initiated clinical trial showed the hair stimulating complex (HSC) safely, statistically and cosmetically promoted significant hair growth, the release said.
According to an exclusive license and supply agreement, Pineworld — an affiliate of Huapont Life Sciences — will focus on clinical development, registration, marketing and sales of the injectable treatment in China. Histogen will receive milestone payments, a transfer price on the product and escalating royalties on future sales.
“We are honored to align with Huapont Life Sciences to bring HSC into China,” Gail Naughton, PhD, CEO of Histogen, said in the release. “With its strong dermatology portfolio, Huapont is an ideal partner for developing and commercializing Histogen’s unique hair growth product to the world’s most populous nation. Hair loss affects men and women around the world, and our goal is to find the best partners in each region to bring solutions to this global problem.”